Skip to content

Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury

Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02690584
Enrollment
16
Registered
2016-02-24
Start date
2016-03-31
Completion date
2021-12-31
Last updated
2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Post-Concussive Symptom, Post-Concussive Syndrome

Keywords

Psychotherapy

Brief summary

The purpose of this open trial is to investigate the feasibility, acceptability, and effect of metacognitive therapy in patients with prolonged post-concussive symptoms after mild traumatic brain injury.

Interventions

Sponsors

Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients with prolonged recovery after mild TBI (GCS \>12) will be recruited to our study if they have post concussive symptoms \> 6 months after injury. Patients will be recruited from an ongoing cohort study investigating mild and moderate TBI at St. Olavs Hospital and Trondheim Municipality Emergency Clinic, and in addition (as of October 2017) among TBI patients at St Olavs Hospital who were not included in the cohort study. Inclusion criteria * Aged ≥between 16 and \< 60 years * Have sustained a traumatic brain injury

Exclusion criteria

* Severe TBI (GCS score 8 or less) * Non fluency in Norwegian * Living outside of Norway * Major other trauma with high risk of disability lasting more than 3 months. * Major incidental intracranial findings in acute MRI e.g. cyst, tumor, malformation, infarctions. * Severe psychiatric, neurological or medical disease, including: Psychotic disorders, bipolar disorder, ongoing severe depressive episode * Personality disorders affecting adherence to the research protocol * Alcohol/drug abuse affecting adherence to the research protocol * Mental retardation, autism or other severe developmental disorders * Prior complicated mild, moderate or severe TBI * Stroke or other acquired brain injuries * Progressive neurological disorders (e.g. Parkinson's disease, MS) * Advanced cancer, heart- or respiratory disease or other somatic diseases that interfere with function. * Major other trauma e.g. spinal cord injury In addition to

Design outcomes

Primary

MeasureTime frame
symptoms assessed by Rivermead Post Concussion Symptoms Questionnairebaseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after completed therapy

Secondary

MeasureTime frame
D-KEFS Trail Making Testbaseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Color-Word Interference Testbaseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
D-KEFS Verbal Fluencybaseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Symbol Digit Modality Testbaseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Behavior Rating Inventory-Adult version (BRIEF-A)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
The metacognitive beliefs questionnaire (MCQ-30)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Fatigue questionnaire (FQ)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Brief Pain Inventory (BPI)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Conners CPT-III2 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Fatigue severity scale (FSS)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
SF-12baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Resilience scale for Adults (RSA)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Epworth sleepiness scale (ESS)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Insomnia severity Index (ISI)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Beck Depression Inventory (BDI)3 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Beck Anxiety Inventory (BAI)3 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Cognitive Attention Syndrome (CAS-1)3 pre-treatment baseline measures, session to session (10 sessions), immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy
Inventory of Interpersonal Problems 64 (IIP-64)baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026